Is SOMX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

272 people get SOMX articles and Market Currents by email alert.

Get email alerts on SOMX »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Why Somaxon Pharmaceuticals Should Be A Double From Here
BuySellShort • Mon, Nov 26, 2012 • 5 Comments
Somaxon Is a Sleeper in the Insomnia Market
Len Zehr • Tue, May 24, 2011 • 7 Comments
Somaxon: A Bargain Buy Pharma
Jeremy Richards • Wed, Dec 1, 2010 • 6 Comments
The Problem With Somaxon's Silenor
Douglas Krohn • Thu, Jun 24, 2010 • 58 Comments

To learn more about Seeking Alpha Pro, click here.

Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way
Greenwich Research Group • Thu, Jun 6 • 49 Comments
Merck's Next-Gen Sleep Disorder Drug - A Blockbuster?
Rx Stocks • Mon, Aug 27, 2012
Debt Burden Makes Horizon Pharma An Attractive Short
Martin Shkreli • Thu, Jul 26, 2012 • 83 Comments
Jazz Pharmaceuticals Can Hit An Interesting Note In 2012
Jessica King Holden • Sun, Feb 26, 2012 • 2 Comments
Alexza And Somaxon: 2 Distressed Biotechs On Sale And Up For Sale
Kinetic Investments • Mon, Dec 19, 2011 • 3 Comments
Top Buy and Sell Ideas Based on Wednesday's Biggest Losers
GuruFundPicks • Thu, Aug 4, 2011 • 3 Comments
What Happens After Intermezzo's Likely FDA Approval
Smith On Stocks • Mon, Jul 11, 2011 • 5 Comments
Future Biotech Superstars
ChartProphet • Wed, Mar 30, 2011 • 12 Comments
Somaxon Pharmaceuticals: Will FDA Approval Ever Pay Off?
Kinetic Investments • Wed, Jan 26, 2011 • 6 Comments
Best Performing Stocks Year to Date
Bespoke Investment Group • Mon, Nov 1, 2010 • 2 Comments
Best and Worst Performing Russell 3,000 Stocks Year to Date
Bespoke Investment Group • Fri, Oct 1, 2010
Best Performing Russell 3,000 Stocks Year to Date
Bespoke Investment Group • Thu, Sep 2, 2010
Somaxon Will Do More Than Just Collect Checks in P&G Deal
EP Vantage • Fri, Aug 27, 2010 • 2 Comments
Somaxon Pharma in Bed With Procter & Gamble
Daniel Long • Thu, Aug 26, 2010 • 3 Comments
Wednesday Options Recap
Frederic Ruffy • Wed, Aug 25, 2010 • 3 Comments
Competitive Technologies: Short Squeeze Coming or Another Leg Down?
David Greene • Wed, Aug 25, 2010 • 29 Comments
15 Heavily Shorted Stocks Reaching an Inflection Point
Kapitall • Wed, Aug 11, 2010 • 2 Comments
Up 100% in 2010
Bespoke Investment Group • Tue, Aug 10, 2010 • 2 Comments
Best and Worst Performing U.S. Stocks YTD
Bespoke Investment Group • Mon, Jul 26, 2010
Friday Options Recap
Frederic Ruffy • Fri, Jul 2, 2010

Somaxon Pharmaceuticals, Inc.'s CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Oct 31, 2012
Somaxon Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012
Somaxon Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Fri, Sep 5, 2008
Somaxon Pharmaceuticals Q4 2007 Earnings Call Transcript
Thu, Apr 17, 2008

Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis

GlobeNewswire (Feb 5, 2013)
Somaxon Announces That Paladin Labs Has Received Approval of New Drug Submission for Silenor (R) in Canada

GlobeNewswire (Dec 17, 2012)
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.

GlobeNewswire (Dec 11, 2012)
Somaxon Pharmaceuticals Reports Third Quarter 2012 Financial Results

GlobeNewswire (Oct 31, 2012)
Somaxon Pharmaceuticals to Report Third Quarter 2012 Results and Conduct Conference Call on Wednesday, October 31

GlobeNewswire (Oct 22, 2012)
Somaxon Pharmaceuticals Approves 1-for-8 Reverse Stock Split and Decrease in the Number of Authorized Shares of Its Common Stock to 25,000,000 Shares

GlobeNewswire (Oct 11, 2012)
Somaxon Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference

GlobeNewswire (Aug 27, 2012)
Somaxon Pharmaceuticals Reports Second Quarter 2012 Financial Results

GlobeNewswire (Aug 7, 2012)
Somaxon Pharmaceuticals to Report Second Quarter 2012 Results and Conduct Conference Call on Tuesday, August 7

GlobeNewswire (Jul 30, 2012)
Somaxon Pharmaceuticals Completes $3.0 Million Registered Direct Offering

GlobeNewswire (Jul 24, 2012)
Somaxon Pharmaceuticals to Raise $3.0 Million in Registered Direct Offering

GlobeNewswire (Jul 20, 2012)
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Zydus

GlobeNewswire (Jul 19, 2012)
Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Mylan and PAR

GlobeNewswire (Jul 17, 2012)
Somaxon Pharmaceuticals Reports First Quarter 2012 Financial Results

Business Wire (May 10, 2012)
Somaxon Pharmaceuticals to Report First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10

Business Wire (Apr 30, 2012)
Somaxon and CJ CheilJedang Announce Silenor® Collaboration in South Korea

Business Wire (Apr 27, 2012)
Somaxon Pharmaceuticals Hires Financial Advisor to Assist in Seeking Strategic Alternatives

Business Wire (Dec 19, 2011)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Nov 19, 2010)
Biotech Stocks: Somaxon paces decliners in drug sector

at MarketWatch.com (Nov 19, 2010)
Biotech Stocks: Exelixis, Cereplast gain; drug indexes split

at MarketWatch.com (Aug 26, 2010)

SOMX vs. ETF Alternatives

Company Description

We are a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. We submitted our NDA for Silenor®... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, February 5, 7:11 PM Somaxon Pharmaceuticals (SOMX) says it's entered into a settlement agreement with Actavis Elizabeth LLC and Actavis to resolve four patent litigation suits involving its Silenor 3 mg and 6 mg tablets. The settlement grants Somaxon an additional seven years protection on its patent, allowing Actavis the right to begin selling a generic version of Silenor on January 1, 2020, or earlier under certain circumstances. Shares +12% AH. Comment! [Healthcare]
Monday, December 17, 2012, 4:51 PM Somaxon Pharmaceuticals (SOMX) says that its licensee Paladin Labs has received approval from Health Canada for its New Drug Submission for its insomnia treatment Silenor. The drug's launch is expected to around mid-2013. Shares +1% AH. Comment! [Healthcare, On the Move]
Tuesday, December 11, 2012, 12:45 PM Midday top 10 gainers: BGMD +146%. SOMX +75%. ACUR +56%. TNS +43%. ULBI +18%. MEAD +16%. ESYS +15%. SZYM +14%. GTXI +13%. CLWR +12%.
Midday top 10 Losers: CBMX -11%. ESIO -11%. AMCN -9%. SEV -9%. GGAL -8%. SPW -8%. TELK -7%. [[JW-A]] -7%. MGLN -7%. SXC -7%. 2 Comments [On the Move]
Tuesday, December 11, 2012, 9:10 AM Somaxon Pharmaceuticals (SOMX) +103.4% premarket after agreeing to be acquired by Pernix Therapeutics (PTX) in a stock-for-stock transaction valued at $25M. Comment! [Healthcare, M&A, On the Move]
Tuesday, December 11, 2012, 9:10 AM Premarket gainers: SOMX +101%. TNS +45%. VE +6%. CLDX +5%. URBN +5%.
Losers: ESIO -19%. Comment! [On the Move]
Monday, November 26, 2012, 12:45 PM Midday top 10 gainers: CBAK +80%. ENMD +23%. ANAD +19%. SSE +17%. HOGS +16%. SBLK +15%. CLSN +14%. SOMX +15%. GALT +14%. ACRX +12%. Midday top 10 Losers: SAB -14%. MMR -13%. CNIT -12%. CCCL -14%. BZ -9%. ZLC -9%. OXF -8%. MEIP -8%. PSTR -8%. AXX -7%. Comment!
Friday, July 20, 2012, 10:38 AM Somaxon Pharmaceuticals (SOMX -19%) gets smacked after saying its selling approximately 9.4M shares of its common stock and warrants in a registered direct offering to purchase up to approximately 4.7M shares of its common stock to institutional investors at $0.32 per share and per warrant. Aggregate proceeds from the transaction will total approximately $3.0M. Comment! [Healthcare, On the Move]
Wednesday, July 18, 2012, 11:43 AM Somaxon (SOMX +83%) soars this morning - after initially surging over 150% in pre-open trading - on the back of yesterday's announcement of its litigation settlement over Silenor with Mylan (MYL +0.8%) and Par Pharmaceuticals. The company added that it sees higher Q2 net sales for Silenor, now seeing revenue of approximately $2.8M to $2.9M, up from reported sales of $2.7M in Q1. Comment! [Healthcare, On the Move]
Tuesday, July 17, 2012, 4:30 PM Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par Pharmaceutical (PRX) involving Silenor 3 mg and 6 mg tablets. The settlement grants MYL the exclusive right to begin selling a generic version of Silenor on January 1, 2020, and PRX the right to begin selling a generic version 180 days after a third party generic version is first sold in the U.S. under a license from Somaxon. Comment! [Healthcare]
Monday, October 3, 2011, 4:50 PM Somaxon Pharmaceuticals (SOMX) jumps in post-trade after saying it had a productive meeting with the FDA relating to the over-the-counter development program for its insomnia drug Silenor, developed jointly with Procter & Gamble (PG). SOMX +22.5% AH. Comment! [Healthcare, On the Move]
Wednesday, February 23, 2011, 9:00 AM Premarket gainers: VRTX +17%. OCLR +10%. CHS +5%. DTV +6%. CTIC +5%. SNV +4%. SOMX +4%.
Losers: SATC -14%. HPQ -9%. CNXT -6%. GRMN -6%. Comment!
Tuesday, February 8, 2011, 9:00 AM Premarket gainers: RHB +46%. KND +26%. CNXT +17%. XIDE +15%. SOMX +6%. CXZ +5%. CPST +5%. MT +5%. BYD +4%. MGM +4%. NTWK +4%. MOTR +4%. CCME +4%.
Losers: BR -12%. GLUU -7%. OLP -6%. TEVA -5%. RNN -5%. BBEP -5%. PPNT -5%. AVP -4%. KTOS -4%. Comment!
Tuesday, November 30, 2010, 9:00 AM Premarket gainers: BEZ +40%. KERX +9%. SOMX +6%. AEZS +4%.
Losers: CTIC -9%. ING -7%. IRE -7%. BBVA -5%. SDRL -5%. AIB -4%. STX -4%. DB -4%. BCS -4%. Comment!
Tuesday, September 7, 2010, 9:00 AM Premarket gainers: ORCL +8%. CASY +7%. RSCR +7%. ARNA +5%. SOMX +5%.
Losers: IDIX -51%. CSKI -26%. BCS -5%. IRE -5%. RTP -4%. ASML -4%. Comment!
Wednesday, August 25, 2010, 9:20 AM Premarket gainers: SOMX +28%. ACTG +7%.
Losers: AIB -7%. IRE -6%. Comment!
Wednesday, August 25, 2010, 8:03 AM Shares of Somaxon Pharmaceuticals (SOMX) are +31.2% premarket after the company announced a co-promotion pact with Procter & Gamble (PG) to market its insomnia drug, Silenor. PG -0.3%. (PR) Comment!

Asif Suria
New Post: Merger Arbitrage Mondays http://bit.ly/Xxoa0B $IN $HLYS $TNS $SOMX $YMI
12/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc. $SOMX $PTX http://bit.ly/T4Vk7V
12/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
Earnings b4 market open: $ACCO $ALT $AG, $ADY $MT $ATPG $BIOD $CSIQ $DYN $GNVC $INO, $NHI $PDCE $RGDX $SOMX $VITC $SNE $SLF $TGX $VITC $WIN
5/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kinetic Investments
$SOMX - Somaxon to explore strategic options, cut jobs. A Biotech Failure - http://reut.rs/u3oiJt
12/19/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

talia1015
Selling looks to be over on SOMX. Starting new long position today.
1/24/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

djn21
Added to SOMX holdings today at 3.21 on relative strength. Stop around 3.10, which is 50% Fib pullback of breakout, 2.60 - 3.60
11/12/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robert J. Hall
$AMD, $NG, $F, $SOMX Market down slightly, but these are up strongly.
11/5/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

djn21
Looks like after a steep decline SOMX maybe have put in a doji bottom yesterday and maybe starting its climb today.
11/5/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Bespoke Investment Group
Best performing Russell 3,000 stocks year to date: http://bit.ly/90LfEB $WNC $SOMX $AERG $IDT $APKT $NFLX $OPEN $LVS $PAR $$
9/2/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Bespoke Investment Group
Reaching the Halfway Mark: http://bit.ly/du6zgJ $$ $NFLX $WNC $SOMX $CPE $GRNB $AERG
6/28/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

SOMX Somaxon Pharmaceuticals, Inc.

SOMX

Somaxon Pharmaceuticals, Inc.